MAPT and Creutzfeldt Jacob disease: Although it could apparently have limited utility in differential diagnosis with other neurodegenerative disorders, further studies using larger cohorts of CJD-affected patients concluded that, in combination with other surrogate biomarkers (i.e., tau and Aβ42), total PrP levels are useful to distinguish them from patients suffering from Alzheimer’s disease [74,75].